SBI Securities Co. Ltd. Purchases Shares of 10,122 Zoetis Inc. (NYSE:ZTS)

SBI Securities Co. Ltd. purchased a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 10,122 shares of the company's stock, valued at approximately $1,649,000.

A number of other hedge funds have also recently bought and sold shares of the company. Darwin Wealth Management LLC purchased a new stake in Zoetis in the 3rd quarter valued at about $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis in the third quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new stake in Zoetis in the third quarter valued at approximately $33,000. Dunhill Financial LLC increased its stake in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after buying an additional 75 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 140 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.

Zoetis Stock Down 1.7 %

ZTS stock traded down $2.94 during midday trading on Wednesday, reaching $166.96. The company had a trading volume of 3,667,422 shares, compared to its average volume of 3,280,360. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33. The company has a 50 day moving average of $166.53 and a two-hundred day moving average of $177.06. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $74.76 billion, a P/E ratio of 30.52, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio is currently 36.56%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of research analyst reports. Stifel Nicolaus dropped their price target on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Leerink Partnrs upgraded Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective on the stock. StockNews.com lowered Zoetis from a "buy" rating to a "hold" rating in a research report on Tuesday, February 25th. Finally, Piper Sandler increased their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.